Consolidation radiotherapy for patients with extended disease small cell lung cancer in a single tertiary institution: impact of dose and perspectives in the era of immunotherapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 2011; 378: 1741-55. doi: 10.1016/S0140-6736(11)60165-7vanMeerbeeck JPFennellDADeRuysscher DKSmall-cell lung cancerLancet201137817415510.1016/S0140-6736(11)60165-7Open DOISearch in Google Scholar
Cancer in Slovenia 2014. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2017.Cancer in Slovenia 2014LjubljanaInstitute of Oncology LjubljanaEpidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2017Search in Google Scholar
Mitchell MD, Aggarwal C, Tsou AY, Torigian DA, Treadwell JR. Imaging for the pretreatment staging of small cell lung cancer: a systematic review. Acad Radiol 2016; 23: 1047-56. doi: 10.1016/j.acra.2016.03.017MitchellMDAggarwalCTsouAYTorigianDATreadwellJRImaging for the pretreatment staging of small cell lung cancer: a systematic reviewAcad Radiol20162310475610.1016/j.acra.2016.03.017Open DOISearch in Google Scholar
Niho S, Fujii H, Murakami K, Nagase S, Yoh K, Goto K, et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer. Lung Cancer 2007; 57: 328-33. 10.1016/j.lungcan.2007.04.001NihoSFujiiHMurakamiKNagaseSYohKGotoKet alDetection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancerLung Cancer2007573283310.1016/j.lungcan.2007.04.001Open DOISearch in Google Scholar
Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, on behalf of the ESMO Guidelines Working Group. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi99-105. doi: 10.1093/annonc/mdt178FrühMDeRuysscher DPopatSCrinòLPetersSFelipEon behalf of the ESMO Guidelines Working Group. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201324Suppl 6vi99–10510.1093/annonc/mdt178Open DOISearch in Google Scholar
National Comprehensive Cancer Network. NCCN guidelines version 2.2020. Small cell lung cancer Nov 15 2019. [Cited 2020 Feb 15]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdfNational Comprehensive Cancer Network. NCCN guidelines version 2.2020. Small cell lung cancer Nov 152019[Cited 2020 Feb 15]. Available fromhttps://www.nccn.org/professionals/physician_gls/pdf/sclc.pdfSearch in Google Scholar
Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007; 357: 664-72. doi: 10.1056/NEJMoa071780SlotmanBFaivre-FinnCKramerGRankinESneeMHattonMet alProphylactic cranial irradiation in extensive small-cell lung cancerN Engl J Med20073576647210.1056/NEJMoa071780Open DOISearch in Google Scholar
Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY5 Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015; 385: 36-42. doi: 10.1016/S0140-6736(14)61085-0SlotmanBJvanTinteren HPraagJOKnegjensJLElSharouni SY5HattonMet alUse of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trialLancet2015385364210.1016/S0140-6736(14)61085-0Open DOISearch in Google Scholar
Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE, et al. Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG Oncology RTOG 0937. J Thorac Oncol 2017; 12: 1561-70. doi: 10.1016/j.jtho.2017.06.015GoreEMHuCSunAYGrimmDFRamalingamSSDunlapNEet alRandomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG Oncology RTOG 0937J Thorac Oncol20171215617010.1016/j.jtho.2017.06.015561065228648948Open DOISearch in Google Scholar
Zhu H, Zhou Z, Wang Y, Bi N, Feng Q, Li J, et al. Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis. Cancer 2011; 117: 5423-31. doi: 10.1002/cncr.26206ZhuHZhouZWangYBiNFengQLiJet alThoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasisCancer201111754233110.1002/cncr.2620621563176Open DOISearch in Google Scholar
Yee D, Butts C, Reiman A, Joy A, Smylie M, Fenton D, et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer. Radiother Oncol 2012; 102: 234-8. doi: 10.1016/j.radonc.2011.08.042YeeDButtsCReimanAJoyASmylieMFentonDet alClinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancerRadiother Oncol2012102234810.1016/j.radonc.2011.08.04221930323Open DOISearch in Google Scholar
Giuliani ME, Atallah S, Sun A, et al. Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy. Clin Lung Cancer 2011; 12: 375-9. doi: 10.1016/j.cllc.2011.03.028GiulianiMEAtallahSSunAet alClinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapyClin Lung Cancer201112375910.1016/j.cllc.2011.03.02821729647Open DOISearch in Google Scholar
Zhang R, Li P, Li Q, Qiao Y, Xu T, Ruan P, et al. Radiotherapy improves the survival of patients with extensive-disease small-cell lung cancer: a propensity score matched analysis of surveillance, epidemiology, and end results database. Cancer Manag Res 2018; 10: 6525-35. doi: 10.2147/CMAR.S174801ZhangRLiPLiQQiaoYXuTRuanPet alRadiotherapy improves the survival of patients with extensive-disease small-cell lung cancer: a propensity score matched analysis of surveillance, epidemiology, and end results databaseCancer Manag Res20181065253510.2147/CMAR.S174801Open DOISearch in Google Scholar
Jeremic B, Gomez-Caamano A, Dubinsky P, Cihoric N, Casas F, Filipovic N. Radiation therapy in extensive stage small cell lung cancer. Front Oncol 2017; 7: 169. doi: 10.3389/fonc.2017.00169JeremicBGomez-CaamanoADubinskyPCihoricNCasasFFilipovicNRadiation therapy in extensive stage small cell lung cancerFront Oncol2017716910.3389/fonc.2017.00169Open DOISearch in Google Scholar
Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?-a review. Transl Lung Cancer Res 2016; 5: 26-38. doi: 10.3978/j.issn.2218-6751.2016.01.13.Alvarado-LunaGMorales-EspinosaDTreatment for small cell lung cancer, where are we now?-a reviewTransl Lung Cancer Res20165263810.3978/j.issn.2218-6751.2016.01.13Open DOISearch in Google Scholar
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018; 379: 2220-9. doi: 10.1056/NEJMoa1809064HornLMansfieldASSzczęsnaAHavelLKrzakowskiMHochmairMJet alFirst-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancerN Engl J Med20183792220910.1056/NEJMoa1809064Open DOISearch in Google Scholar
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum–etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019; 394: 1929-39. doi: 10.1016/S0140-6736(19)32222-6Paz-AresLDvorkinMChenYReinmuthNHottaKTrukhinDet alDurvalumab plus platinum–etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialLancet201939419293910.1016/S0140-6736(19)32222-6Open DOISearch in Google Scholar
Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, Dagovic A, et al. Role of radiation therapy in the combined modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999; 17: 2092-9. doi: 10.1200/JCO.1999.17.7.2092JeremicBShibamotoYNikolicNMilicicBMilisavljevicSDagovicAet alRole of radiation therapy in the combined modality treatment of patients with extensive disease small-cell lung cancer: a randomized studyJ Clin Oncol1999172092910.1200/JCO.1999.17.7.209210561263Open DOISearch in Google Scholar
Palma DA, Warner A, Louie AV, Senan S, Slotman B, Rodrigues GB. Thoracic radiotherapy for extensive stage small-cell lung cancer: a meta-analysis. Clin Lung Cancer 2016; 17: 239-44. doi: 10.1016/j.cllc.2015.09.00PalmaDAWarnerALouieAVSenanSSlotmanBRodriguesGBThoracic radiotherapy for extensive stage small-cell lung cancer: a meta-analysisClin Lung Cancer2016172394410.1016/j.cllc.2015.09.00Open DOISearch in Google Scholar
Rathod S, Jeremic B, Dubey A, Giuliani M, Bashir B, Chowdhury A, et al. Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials. Eur J Cancer 2019; 110: 110-9. doi: 10.1016/j.ejca.2019.01.003RathodSJeremicBDubeyAGiulianiMBashirBChowdhuryAet alRole of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trialsEur J Cancer2019110110910.1016/j.ejca.2019.01.00330785014Open DOISearch in Google Scholar
Xu LM, Zhao LJ, Charles B , Simone CB 2nd, Cheng C, Kang M, et al. Receipt of thoracic radiation therapy and radiotherapy dose are correlated with outcomes in a retrospective study of three hundred and six patients with extensive stage small-cell lung cancer. Radiother Oncol 2017; 125: 331-7. doi: 10.1016/j.radonc.2017.10.005XuLMZhaoLJCharlesBSimoneCB2ndChengCKangMet alReceipt of thoracic radiation therapy and radiotherapy dose are correlated with outcomes in a retrospective study of three hundred and six patients with extensive stage small-cell lung cancerRadiother Oncol2017125331710.1016/j.radonc.2017.10.00529079309Open DOISearch in Google Scholar
Hasan S, Renz P, Turrisi A, Colonias A, Finley G, Wegner RE. Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): A National Cancer Database (NCDB) propensity-matched analysis. Lung Cancer 2018; 124: 283-90. doi: 10.1016/j.lungcan.2018.08.016HasanSRenzPTurrisiAColoniasAFinleyGWegnerREDose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): A National Cancer Database (NCDB) propensity-matched analysisLung Cancer20181242839010.1016/j.lungcan.2018.08.016742560230268474Open DOISearch in Google Scholar
Xu LM, Cheng C, Kang M, Luo J, Gong LL, Pang QS, et al. Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer. Sci Rep 2017; 7: 9255. doi: 10.1038/s41598-017-09775-0XuLMChengCKangMLuoJGongLLPangQSet alThoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancerSci Rep20177925510.1038/s41598-017-09775-0Open DOISearch in Google Scholar
Fukui T, Itabashi M, Ishihara M, Hiyoshi Y, Kasajima M, Igawa S, et al. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer. BMC Cancer 2016; 16: 197. doi:10.1186/s12885-016-2222-4FukuiTItabashiMIshiharaMHiyoshiYKasajimaMIgawaSet alPrognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancerBMC Cancer20161619710.1186/s12885-016-2222-4Open DOISearch in Google Scholar
Luo J, Xu L, Zhao L, Cao Y, Pang Q, Wang J, et al. Timing of thoracic radiotherapy in the treatment of extensive-stage small-cell lung cancer: important or not? Radiat Oncol 2017; 12: 42. doi: 10.1186/s13014-017-0779-yLuoJXuLZhaoLCaoYPangQWangJet alTiming of thoracic radiotherapy in the treatment of extensive-stage small-cell lung cancer: important or not?Radiat Oncol2017124210.1186/s13014-017-0779-yOpen DOISearch in Google Scholar
De Ruysscher D, Lueza B, Le Péchoux C, Johnson DH, O’Brien M, Murray N, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol 2016; 27: 1818-28. doi: 10.1093/annonc/mdw263De RuysscherDLuezaBLe PéchouxCJohnsonDHO’BrienMMurrayNet alImpact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysisAnn Oncol20162718182810.1093/annonc/mdw263Open DOISearch in Google Scholar
Stanic K, Kovac V. Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana. Radiol Oncol 2010; 44: 180-6. doi: 10.2478/v10019-010-0038-4StanicKKovacVProphylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology LjubljanaRadiol Oncol201044180610.2478/v10019-010-0038-4Open DOISearch in Google Scholar
Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18: 663-71. doi: 10.1016/S1470-2045(17)30230-9TakahashiTYamanakaTSetoTHaradaHNokiharaHSakaHet alProphylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trialLancet Oncol2017186637110.1016/S1470-2045(17)30230-9Open DOISearch in Google Scholar
Rusthoven CG, Kavanagh BD. Prophylactic cranial irradiation (PCI) versus active MRI surveillance for small cell lung cancer: the case for equipoise. J Thorac Oncol 2017; 12: 1746-54. doi: 10.1016/j.jtho.2017.08.016RusthovenCGKavanaghBDProphylactic cranial irradiation (PCI) versus active MRI surveillance for small cell lung cancer: the case for equipoiseJ Thorac Oncol20171217465410.1016/j.jtho.2017.08.016Open DOISearch in Google Scholar
Hui R, Gandhi L, Costa EC, Felip E, Ahn MJ, Eder JP, et al. Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). J Clin Oncol 2016; 34: Abstr nr 9026.HuiRGandhiLCostaECFelipEAhnMJEderJPet alLong-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro)J Clin Oncol201634Abstr nr 902610.1200/JCO.2016.34.15_suppl.9026Search in Google Scholar
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-28. doi: 10.1056/NEJMoa1501824GaronEBRizviNAHuiRLeighlNBalmanoukianASEderJPet alPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med201537220182810.1056/NEJMoa1501824Open DOISearch in Google Scholar
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-50. doi: 10.1016/S0140-6736(15)01281-7HerbstRSBaasPKimDWFelipEPérez-GraciaJLHanJYet alPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet201638715405010.1016/S0140-6736(15)01281-7Open DOISearch in Google Scholar
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-33. doi: 10.1056/NEJMoa1606774ReckMRodríguez-AbreuDRobinsonAGHuiRCsősziTFülöpAet alPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med201637518233310.1056/NEJMoa1606774Open DOISearch in Google Scholar
Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016; 17: 1497-508. doi: 10.1016/S1470-2045(16)30498-3LangerCJGadgeelSMBorghaeiHPapadimitrakopoulouVAPatnaikAPowellSFet alCarboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyLancet Oncol201617149750810.1016/S1470-2045(16)30498-3Open DOISearch in Google Scholar
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35. doi: 10.1056/NEJMoa1504627BrahmerJReckampKLBaasPCrinòLEberhardtWEPoddubskayaEet alNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med20153731233510.1056/NEJMoa1504627Open DOISearch in Google Scholar
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-39. doi: 10.1056/NEJMoa1507643BorghaeiHPaz-AresLHornLSpigelDRSteinsMReadyNEet alNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med201537316273910.1056/NEJMoa1507643Open DOISearch in Google Scholar
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387: 1837-46. doi: 10.1016/S0140-6736(16)00587-0FehrenbacherLSpiraABallingerMKowanetzMVansteenkisteJMazieresJet alAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLancet201638718374610.1016/S0140-6736(16)00587-0Open DOISearch in Google Scholar
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379: 2342-50. doi: 10.1056/NEJMoa1809697AntoniaSJVillegasADanielDVicenteDMurakamiSHuiRet alOverall survival with durvalumab after chemoradiotherapy in stage III NSCLCN Engl J Med201837923425010.1056/NEJMoa180969730280658Open DOISearch in Google Scholar
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med 2017; 377: 1919-29. doi: 10.1056/NEJMoa1709937AntoniaSJVillegasADanielDVicenteDMurakamiSHuiRet alDurvalumab after chemoradiotherapy in stage III non–small-cell lung cancerN Engl J Med201737719192910.1056/NEJMoa170993728885881Open DOISearch in Google Scholar
Verma V, Cushman TR, Selek U, Tang C, Welsh JW. Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials. Int J Radiat Oncol Biol Phys 2018; 101: 1141-8. doi: 10.1016/j.ijrobp.2018.04.054VermaVCushmanTRSelekUTangCWelshJWSafety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II TrialsInt J Radiat Oncol Biol Phys20181011141810.1016/j.ijrobp.2018.04.05430012526Open DOISearch in Google Scholar
Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 2015; 1: 1325-32. doi: 10.1001/jamaoncol.2015.2756DemariaSGoldenEBFormentiSCRole of local radiation therapy in cancer immunotherapyJAMA Oncol2015113253210.1001/jamaoncol.2015.275626270858Open DOISearch in Google Scholar
Vrankar M, Stanic K. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. Radiol Oncol 2018; 52: 281-8. doi: 10.2478/raon-2018-0009VrankarMStanicKLong-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapyRadiol Oncol201852281810.2478/raon-2018-0009613736730210037Open DOISearch in Google Scholar
Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 2015; 16: e498-509. doi: 10.1016/S1470-2045(15)00007-8SharabiABLimMDeWeeseTLDrakeCGRadiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergyLancet Oncol201516e49850910.1016/S1470-2045(15)00007-8Open DOISearch in Google Scholar
